Kilitch Drugs (India) Limited Announces 1:1 Bonus Share Allotment

Kilitch Drugs (India) Limited has announced a significant corporate action with its Board of Directors approving a bonus share allotment in a 1:1 ratio. The decision was taken during the board meeting held on March 25, 2026, marking a major milestone for the pharmaceutical company's shareholders.

Bonus Share Allotment Details

The company has approved the allotment of 1,74,80,782 bonus equity shares of Rs. 10 each to its shareholders. Under the 1:1 ratio scheme, shareholders will receive one bonus equity share of Rs. 10 each for every one equity share of Rs. 10 each currently held. The record date for determining eligible shareholders has been fixed as March 24, 2026.

The bonus equity shares will rank pari-passu in all respects with the existing fully paid-up equity shares of the company, ensuring equal rights and benefits for all shareholders.

Impact on Share Capital Structure

The bonus issue has resulted in a significant expansion of the company's equity base:

Particulars No. of Shares Face Value (per share in Rs.) Amount (in Rs.) Paid-up Share Capital (Pre-Bonus Issue) 17480782 10 174807820 Paid-up Share Capital (Post Bonus Issue) 34961564 10 349615640

The paid-up equity share capital has effectively doubled from Rs. 17.48 crore to Rs. 34.96 crore following the bonus share allotment.

Board Meeting Proceedings

The board meeting commenced at 10:30 hours and concluded at 12:05 hours on March 25, 2026. The decision was communicated to both BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The announcement was signed by Mukund Mehta, Managing Director of Kilitch Drugs (India) Limited, bearing DIN: 00147876. This bonus share allotment represents the company's commitment to rewarding its shareholders while strengthening its equity structure for future growth initiatives.

Kilitch drugs (India) Limited successfully conducted its Extra-Ordinary General Meeting on March 13, 2026, addressing significant corporate restructuring initiatives through video conferencing. Following overwhelming shareholder approval for bonus share issuance, the pharmaceutical company has now announced the record date for determining eligible shareholders.

Record Date and Allotment Timeline

The company has officially fixed March 24, 2026 as the record date for determining shareholders entitled to receive bonus equity shares in the ratio of 1:1. This announcement was made through a regulatory filing to BSE Limited and National Stock Exchange of India Limited under Regulation 42 of SEBI regulations.

Parameter: Details Record Date: March 24, 2026 (Tuesday) Deemed Allotment Date: March 25, 2026 (Wednesday) Bonus Ratio: 1:1 (One bonus share for every existing share) Share Face Value: ₹10 per equity share

Eligibility Criteria for Bonus Shares

Shareholders whose names appear on the company's register of members for physical shares and on the register of beneficial owners maintained by depositories for electronic shares as of closing hours on March 24, 2026 will be entitled to receive the bonus equity shares. The bonus issue offers existing shareholders one additional equity share of ₹10 each for every share held.

EGM Resolutions and Voting Results

The bonus share proposal was approved during the Extra-Ordinary General Meeting held on March 13, 2026, from 11:30 am to 11:42 am through video conferencing. Both major resolutions presented to shareholders received overwhelming support.

Resolution: Description Votes in Favor Votes Against Result Resolution No. 1: Increase authorized capital and amend Capital Clause of Memorandum of Association 12,396,194 (100.00%) 1 (0.00%) Passed Resolution No. 2: Approve issue and allotment of bonus shares in 1:1 ratio 12,396,194 (100.00%) 1 (0.00%) Passed

Shareholder Participation and Compliance

The EGM witnessed participation from 48 members, including 3 promoter group members and 45 public shareholders. The meeting was chaired by Mr. Mukund Mehta, Managing Director, with comprehensive participation from the leadership team including Mrs. Mira Mehta, Mr. Bhavin Mehta, and three Independent Directors.

Voting Details: Information Total Shares Outstanding: 17,480,782 Total Votes Polled: 12,396,195 (70.91%) Promoter Participation: 100.00% Public Institution Participation: 66.67%

The record date announcement, signed by Managing Director Mukund Mehta, ensures full compliance with regulatory requirements and marks the completion of the bonus share issuance process that will strengthen the company's capital structure while rewarding existing shareholders.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.